MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

PURPOSE: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer. PATIENTS AND ME...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Chien, A. Jo, Tripathy, Debasish, Albain, Kathy S., Symmans, W. Fraser, Rugo, Hope S., Melisko, Michelle E., Wallace, Anne M., Schwab, Richard, Helsten, Teresa, Forero-Torres, Andres, Stringer-Reasor, Erica, Ellis, Erin D., Kaplan, Henry G., Nanda, Rita, Jaskowiak, Nora, Murthy, Rashmi, Godellas, Constantine, Boughey, Judy C., Elias, Anthony D., Haley, Barbara B., Kemmer, Kathleen, Isaacs, Claudine, Clark, Amy S., Lang, Julie E., Lu, Janice, Korde, Larissa, Edmiston, Kirsten K., Northfelt, Donald W., Viscusi, Rebecca K., Yee, Douglas, Perlmutter, Jane, Hylton, Nola M., van’t Veer, Laura J., DeMichele, Angela, Wilson, Amy, Peterson, Garry, Buxton, Meredith B., Paoloni, Melissa, Clennell, Julia, Berry, Scott, Matthews, Jeffrey B., Steeg, Katherine, Singhrao, Ruby, Hirst, Gillian L., Sanil, Ashish, Yau, Christina, Asare, Smita M., Berry, Donald A., Esserman, Laura J.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2020
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106976/
https://ncbi.nlm.nih.gov/pubmed/32031889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01027
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker